[{"id":"adaptimmune","kind":"company","name":"Adaptimmune","route":"/companies/adaptimmune/","commit":"708b8acc4f","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on thirty more institutions and thirty companies","file":"src/data/companies.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.adaptimmune.com\" }]"}]},{"id":"adaptimmune","kind":"company","name":"Adaptimmune","route":"/companies/adaptimmune/","commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts","type":"added","fields":[{"field":"id"},{"field":"label"},{"field":"kind"}]},{"id":"adaptimmune","kind":"company","name":"Adaptimmune","route":"/companies/adaptimmune/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/companies.ts","type":"changed","fields":[{"field":"tldr","before":"\"Developer of Tecelra, the first TCR-T for a solid tumour; sold US rights to US WorldMeds in 2025 amid financial distress.\"","after":"\"Adaptimmune developed Tecelra, the first TCR-T for a solid tumour, and sold the US rights to US WorldMeds in 2025 amid financial distress.\""}]}]